Examining the Data From Key Clinical Trials, and Practical Strategies

Video

Chapter 2- Examining the Data From Key Clinical Trials, and Practical Strategies-
Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected
      Recent Videos
      4 experts in this video
      Imaging Quality in Prostate Cancer: Impact on Treatment Decision-Making
      4 experts in this video
      Selecting the Optimal PSMA PET Imaging Agent: Clinical Considerations and Data-Driven Decisions
      4 experts in this video
      PSMA PET Imaging Agents: Image Quality and Diagnostic Performance
      4 experts in this video
      The Evolving Role of PSMA PET in Prostate Cancer Imaging and Management
      Protecting Sexual Function Via The Hood Technique in Prostate Cancer
      Protecting Sexual Function Via The Hood Technique in Prostate Cancer
      Hood Technique Improves Earlier Continence in Prostate Cancer Surgery
      Hood Technique Improves Earlier Continence in Prostate Cancer Surgery
      Standardizing surgical outcomes and better training oncologic surgeons may be accomplished through the use of AI.
      AI Use in Surgeries for Prostate Cancer May Help Standardize Outcomes
      The poly-ICLC trial seeks to develop a delivery mechanism to prostate cancer through different biomarkers.
      Vaccine Trials Ongoing in Locally Advanced Oligometastatic Prostate Cancer
      Ablative technology may generate an immune response that can be enhanced via injected immunotherapy in patients with solid tumors.
      Oncolysis/Immunotherapy Shows ‘Significant’ Data in Prostate Cancer
      A phase 1 trial assessed the use of PSCA-directed CAR T cells in patients with metastatic castration-resistant prostate cancer.
      Tanya B. Dorff, MD, on Phase 1 Trial of CAR T-Cell Therapy in mCRPC
      Related Content
      Results from PSMAfore show that lutetium Lu 177 vipivotide tetraxetan elicited a median rPFS of 9.3 months vs 5.6 months with ARPI in prostate cancer.

      FDA Approves Radioligand Therapy in PSMA–Positive, Castration-Resistant PC

      Tim Cortese
      March 28th 2025
      Article

      Results from PSMAfore show that lutetium Lu 177 vipivotide tetraxetan elicited a median rPFS of 9.3 months vs 5.6 months with ARPI in prostate cancer.

      Navigating Treatment Intensification in Metastatic Hormone-Sensitive Prostate Cancer

      Navigating Treatment Intensification in Metastatic Hormone-Sensitive Prostate Cancer

      Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;David Morris, MD, MS;Tanya B. Dorff, MD;Mark T. Fleming, MD
      March 5th 2025
      Podcast

      A patient case of a 50-year-old man with hormone-sensitive prostate cancer sparked a debate among oncologists regarding the best course of action.

      The adverse effect profile was similar among patients with prostate cancer using NeuroSAFE-assisted RARP vs standard RARP.

      NeuroSAFE Improves Erectile Function, Urinary Continence in Prostate Cancer

      Roman Fabbricatore
      March 24th 2025
      Article

      The adverse effect profile was similar among patients with prostate cancer using NeuroSAFE-assisted RARP vs standard RARP.

      AI tools may show utility in areas such as prostate diagnostic imaging, pathology, and treatment outcome predictions.

      Leveraging Artificial Intelligence Evolutions in Prostate Cancer Care

      James B. Yu, MD, MHS, FASTRO;Julian C. Hong, MD, MS
      July 1st 2024
      Podcast

      AI tools may show utility in areas such as prostate diagnostic imaging, pathology, and treatment outcome predictions.

      Prior data support the ability of PATHOMIQ_PRAD to predict patients at a high risk of biochemical recurrence and metastasis.

      New Partnership May Expand Use of Prostate Cancer AI Technology Platform

      Russ Conroy
      February 27th 2025
      Article

      Prior data support the ability of PATHOMIQ_PRAD to predict patients at a high risk of biochemical recurrence and metastasis.

      Results from the phase 1/2a SeCuRE trial support the FDA decision for patients with metastatic castration-resistant prostate cancer.

      Cu-67 SAR-bisPSMA Granted Fast Track Designation for Metastatic CRPC

      Roman Fabbricatore
      February 20th 2025
      Article

      Results from the phase 1/2a SeCuRE trial support the FDA decision for patients with metastatic castration-resistant prostate cancer.